

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. (currently amended) A regime or regimen for causing contractile fiber decontraction or relaxation to loosen and/or relax cutaneous and/or subcutaneous human skin tissue, comprising administering to a candidate subject with signs of aging of the skin in need of such regime or regimen, a thus-effective amount of at least one inhibitor of at least one calcium channel.

2-3. (cancelled)

4. (previously presented) The regime or regimen as defined by Claim 1, wherein said loosening and/or relaxing of cutaneous and/or subcutaneous human skin tissue smooths the skin.

5-23. (cancelled)

24. (previously presented) The regime or regimen of Claim 1, comprising topically applying said effective amount of a least one inhibitor of at least one calcium channel onto the skin of said candidate subject.

25. (previously presented) The regime or regimen of Claim 1, wherein said at least one inhibitor of at least one calcium channel comprises an agent active on the plasma membrane, a calcium-influx inhibitor, a calcium-complexing agent, or an agent active inside the cell, which have an effect on the release of intracellular calcium reserves or an inhibition of the formation of the calcium/calmodulin complex.

26. (previously presented) The regime or regimen of Claim 25, wherein said at least one inhibitor of at least one calcium channel comprises a phenylalkylamine, a dihydropyridine, a benzothiazepine, or a diphenylpiperazine.

27. (currently amended) The regime or regimen as defined by Claim 26, wherein said at least one inhibitor of at least one calcium channel comprises verapamil, anipamil, gallopamil, devapamil, falipamil, tiapamil, nifedipine, amlodipine, dazodipine, felodipine, isradipine, lanicardipine, nimodipine, nisoldipine, nitrendipine, ryosidine, Diltiazem, cinnarizine, or flunarizine.

28. (previously presented) The regime or regimen as defined by Claim 27, wherein said at least one inhibitor of at least one calcium channel comprises verapamil.

29. (previously presented) The regime or regimen as defined by Claim 25, wherein said at least one inhibitor of at least one calcium channel comprises an agent active on the sarcoplasmic reticulum, a calmodulin antagonist, a naphthalene compound, or a dopamine antagonist.

30. (previously presented) The regime or regimen as defined by Claim 29, said at least one inhibitor of at least one calcium channel comprises dantrolene, TMB-8, phenothiazine, trifluoperazine, chlorpromazine, dibucaine, pimozide, haloperidol, or calmidazolium.

31. (previously presented) The regime or regimen of Claim 1, comprising subcutaneously and/or intradermally injecting said at least one inhibitor of at least one calcium channel.

32. (currently amended) A regime or regimen for loosening and/or relaxing cutaneous and/or subcutaneous human skin tissue, comprising administering to a candidate subject with signs of aging of the skin in need of such regime or regimen, a thus-effective amount of at least one inhibitor of at least one calcium channel and a keratolytic active agent.

33. (previously presented) The regime or regimen of Claim 32, wherein said keratolytic agent comprises an  $\alpha$ -hydroxy acid, a  $\beta$ -hydroxy acid and/or a retinoid.

34. (new) The regime or regimen as defined by Claim 32, wherein said loosening and/or relaxing of cutaneous and/or subcutaneous human skin tissue smooths the skin.

35. (new) The regime or regimen of Claim 32, comprising topically applying said effective amount of a least one inhibitor of at least one calcium channel onto the skin of said candidate subject.

36. (new) The regime or regimen of Claim 32, wherein said at least one inhibitor of at least one calcium channel comprises an agent active on the plasma membrane, a calcium-influx inhibitor, a calcium-complexing agent, or an agent active inside the cell, which have an effect on the release of intracellular calcium reserves or an inhibition of the formation of the calcium/calmodulin complex.

37. (new) The regime or regimen of Claim 36, wherein said at least one inhibitor of at least one calcium channel comprises a phenylalkylamine, a dihydropyridine, a benzothiazepine, or a diphenylpiperazine.

38. (new) The regime or regimen as defined by Claim 37, wherein said at least one inhibitor of at least one calcium channel comprises verapamil, anipamil, gallopamil, devapamil, falipamil, tiapamil, nifedipine, amlodipine, dazodipine, felodipine, isradipine, lanicardipine, nimodipine, nisoldipine, nitrendipine, ryosidine, Diltiazem, cinnarizine, or flunarizine.

39. (new) The regime or regimen as defined by Claim 38, wherein said at least one inhibitor of at least one calcium channel comprises verapamil.

40. (new) The regime or regimen as defined by Claim 36, wherein said at least one inhibitor of at least one calcium channel comprises an agent active on the sarcoplasmic reticulum, a calmodulin antagonist, a naphthalene compound, or a dopamine antagonist.

41. (new) The regime or regimen as defined by Claim 40, said at least one inhibitor of at least one calcium channel comprises dantrolene, TMB-8, phenothiazine, trifluoperazine, chlorpromazine, dibucaine, pimozide, haloperidol, or calmidazolium.

42. (new) The regime or regimen of Claim 32, comprising subcutaneously and/or intradermally injecting said at least one inhibitor of at least one calcium channel.